PIK3CA and breast cancer: Taselisib, a selective inhibitor of class I PI3Kα, δ-, and γ-isoforms, and ipatasertib, an AKT inhibitor, plus anti-microtubule chemotherapy showed significant synergism in terms of antiproliferative, pro-apoptotic, and anti-metastatic effects in PIK3CA-mutated BC cells (Morgillo et al., 2017[34]).